Aquavit Files Investigation of New Drug for New Botulinum Toxin
Aquavit Pharmaceuticals, Inc. has submitted to the U.S. FDA an Investigation of New Drug package for a new botulinum toxin, DTX-021.
Read MorePosted by Keri Stephens | Mar 25, 2022 | Botox |
Aquavit Pharmaceuticals, Inc. has submitted to the U.S. FDA an Investigation of New Drug package for a new botulinum toxin, DTX-021.
Read MorePosted by Debbie Overman | Aug 14, 2020 | Botox, Research, Scar Treatment |
Botulinum toxin type A can lead to significant clinical and cosmetic improvement in patients with hypertrophic scars, according to study research published in the Journal of Cosmetic Dermatology, per Dermatology Advisor.
Read MorePosted by Debbie Overman | Nov 8, 2018 | Scar Treatment |
Long lauded for its ability to reduce the appearance of wrinkles, botulinum toxin is now being considered for reducing scarring, Dermatology Times reports.
Read MorePosted by Debbie Overman | Oct 24, 2018 | Body Makeover, Research |
While botulinum toxin is most commonly used to relieve frowns and wrinkles, it is increasingly being shown to be associated with improving mood and relationships, a researcher says, in Dermatology Times.
Read MorePosted by Debbie Overman | Jan 30, 2018 | Body Makeover, Botox |
Physicians at the Medical University of South Carolina (MUSC) report the first pediatric use of a treatment to reverse complications from botulinum toxin therapy.
Read More